Carrie Caswell1, Corey T McMillan1, Sharon X Xie1, Vivianna M Van Deerlin1, EunRan Suh1, Edward B Lee1, John Q Trojanowski1, Virginia M-Y Lee1, David J Irwin1, Murray Grossman1, Lauren M Massimo2. 1. From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. From the Department of Biostatistics, Epidemiology, and Informatics (C.C., S.X.X.), Department of Neurology (C.T.M., D.J.I., M.G., L.M.M.), Penn Frontotemporal Degeneration Center (C.T.M., D.J.I., M.G., L.M.M.), Translational Neuropathology Research Laboratory (E.B.L.), Department of Pathology and Laboratory Medicine (V.M.V.D., E.B.L., J.Q.T., V.M.-Y.L.), and Center for Neurodegenerative Disease Research (V.M.V.D., E.S., E.B.L., J.Q.T., V.M.-Y.L.), Perelman School of Medicine, University of Pennsylvania, Philadelphia. lmassimo@upenn.edu.
Abstract
OBJECTIVE: To determine autosomal dominant genetic predictors of survival in individuals with behavioral variant frontotemporal degeneration (bvFTD). METHODS: A retrospective chart review of 174 cases with a clinical phenotype of bvFTD but no associated elementary neurologic features was performed, with diagnosis either autopsy-confirmed (n = 57) or supported by CSF evidence of non-Alzheimer pathology (n = 117). Genetic analysis of the 3 most common genes with pathogenic autosomal dominant mutations associated with frontotemporal degeneration was performed in all patients, which identified cases with C9orf72 expansion (n = 28), progranulin (GRN) mutation (n = 12), and microtubule-associated protein tau (MAPT) mutation (n = 10). Cox proportional hazards regressions were used to test for associations between survival and mutation status, sex, age at symptom onset, and education. RESULTS: Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a GRN mutation (HR 2.423, 95% CI 1.237, 4.744), MAPT mutation (HR 8.056, 95% CI 2.938, 22.092), and C9orf72 expansion (HR 1.832, 95% CI 1.034, 3.244) were each individually associated with shorter survival relative to sporadic bvFTD. A mutation on the MAPT gene results in an earlier age at onset than a C9orf72 expansion or mutation on the GRN gene (p = 0.016). CONCLUSIONS: Our findings suggest that autosomal dominantly inherited mutations, modulated by age at symptom onset, associate with shorter survival among patients with bvFTD. We suggest that clinical trials and clinical management should consider mutation status and age at onset when evaluating disease progression.
OBJECTIVE: To determine autosomal dominant genetic predictors of survival in individuals with behavioral variant frontotemporal degeneration (bvFTD). METHODS: A retrospective chart review of 174 cases with a clinical phenotype of bvFTD but no associated elementary neurologic features was performed, with diagnosis either autopsy-confirmed (n = 57) or supported by CSF evidence of non-Alzheimer pathology (n = 117). Genetic analysis of the 3 most common genes with pathogenic autosomal dominant mutations associated with frontotemporal degeneration was performed in all patients, which identified cases with C9orf72 expansion (n = 28), progranulin (GRN) mutation (n = 12), and microtubule-associated protein tau (MAPT) mutation (n = 10). Cox proportional hazards regressions were used to test for associations between survival and mutation status, sex, age at symptom onset, and education. RESULTS: Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a GRN mutation (HR 2.423, 95% CI 1.237, 4.744), MAPT mutation (HR 8.056, 95% CI 2.938, 22.092), and C9orf72 expansion (HR 1.832, 95% CI 1.034, 3.244) were each individually associated with shorter survival relative to sporadic bvFTD. A mutation on the MAPT gene results in an earlier age at onset than a C9orf72 expansion or mutation on the GRN gene (p = 0.016). CONCLUSIONS: Our findings suggest that autosomal dominantly inherited mutations, modulated by age at symptom onset, associate with shorter survival among patients with bvFTD. We suggest that clinical trials and clinical management should consider mutation status and age at onset when evaluating disease progression.
Authors: J L Whitwell; B F Boeve; S D Weigand; M L Senjem; J L Gunter; M C Baker; M DeJesus-Hernandez; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; C R Jack; K A Josephs Journal: Eur J Neurol Date: 2015-02-12 Impact factor: 6.089
Authors: David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-12-31 Impact factor: 17.088
Authors: David J Irwin; Corey T McMillan; Jon B Toledo; Steven E Arnold; Leslie M Shaw; Li-San Wang; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman Journal: Arch Neurol Date: 2012-08
Authors: William T Hu; Harro Seelaar; Keith A Josephs; David S Knopman; Bradley F Boeve; Eric J Sorenson; Leo McCluskey; Lauren Elman; Helenius J Schelhaas; Joseph E Parisi; Benno Kuesters; Virginia M-Y Lee; John Q Trojanowski; Ronald C Petersen; John C van Swieten; Murray Grossman Journal: Arch Neurol Date: 2009-11
Authors: Elisabeth M Wood; Dana Falcone; Eunran Suh; David J Irwin; Alice S Chen-Plotkin; Edward B Lee; Sharon X Xie; Vivianna M Van Deerlin; Murray Grossman Journal: JAMA Neurol Date: 2013-11 Impact factor: 18.302
Authors: Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: David M Cash; Martina Bocchetta; David L Thomas; Katrina M Dick; John C van Swieten; Barbara Borroni; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Caroline Graff; Fabrizio Tagliavini; Giovanni B Frisoni; Robert Laforce; Elizabeth Finger; Alexandre de Mendonça; Sandro Sorbi; Martin N Rossor; Sebastien Ourselin; Jonathan D Rohrer Journal: Neurobiol Aging Date: 2017-10-19 Impact factor: 4.673
Authors: Philip Wade Tipton; Angela B Deutschlaender; Rodolfo Savica; Michael G Heckman; Danielle E Brushaber; Bradford C Dickerson; Ralitza H Gavrilova; Daniel H Geschwind; Nupur Ghoshal; Jonathan Graff-Radford; Neill R Graff-Radford; Murray Grossman; Ging-Yuek R Hsiung; Edward D Huey; David John Irwin; David T Jones; David S Knopman; Scott M McGinnis; Rosa Rademakers; Eliana Marisa Ramos; Leah K Forsberg; Hilary W Heuer; Chiadi Onyike; Carmela Tartaglia; Kimiko Domoto-Reilly; Erik D Roberson; Mario F Mendez; Irene Litvan; Brian S Appleby; Ian Grant; Daniel Kaufer; Adam L Boxer; Howard J Rosen; Brad F Boeve; Zbigniew K Wszolek Journal: Neurology Date: 2022-07-05 Impact factor: 11.800
Authors: Russell P Sawyer; Hillarey K Stone; Hanan Salim; Xiaoming Lu; Matthew T Weirauch; Leah Kottyan Journal: Medicine (Baltimore) Date: 2022-10-14 Impact factor: 1.817
Authors: Ignacio Illán-Gala; Kaitlin B Casaletto; Sergi Borrego-Écija; Eider M Arenaza-Urquijo; Amy Wolf; Yann Cobigo; Sheng Yang M Goh; Adam M Staffaroni; Daniel Alcolea; Juan Fortea; Rafael Blesa; Jordi Clarimon; Maria Florencia Iulita; Anna Brugulat-Serrat; Albert Lladó; Lea T Grinberg; Katherine Possin; Katherine P Rankin; Joel H Kramer; Gil D Rabinovici; Adam Boxer; William W Seeley; Virginia E Sturm; Maria Luisa Gorno-Tempini; Bruce L Miller; Raquel Sánchez-Valle; David C Perry; Alberto Lleó; Howard J Rosen Journal: Alzheimers Dement Date: 2021-02-16 Impact factor: 16.655
Authors: Christian Hinderer; Rod Miller; Cecilia Dyer; Julia Johansson; Peter Bell; Elizabeth Buza; James M Wilson Journal: Ann Clin Transl Neurol Date: 2020-09-16 Impact factor: 4.511